Inter-eye comparison of retinal vascular growth rate and angiographic findings following unilateral bevacizumab treatment

2021 ◽  
pp. 112067212110640
Author(s):  
Sadik Etka Bayramoglu ◽  
Nihat Sayin
Keyword(s):  
Fluorescein Angiography ◽  
Intravitreal Bevacizumab ◽  
Treated Group ◽  
Progression Rate ◽  
Bevacizumab Treatment ◽  
Postmenstrual Age ◽  
Pre Treatment ◽  
Fundus Photographs ◽  
Angiographic Findings ◽  
Retinal Vascularization

Purpose To compare retinal vascularization progression rate, final retinal vascularization, and fluorescein angiography (FA) findings in infants who received intravitreal bevacizumab (IVB) treatment in one eye and with spontaneous regression in the other eye. Methods Thirty eyes of 15 infants who underwent IVB in one eye due to asymmetric retinopathy of prematurity, and who had pre-treatment fundus photographs and fluorescein angiography images were included in the study. Horizontal disc diameter (DD), optic disc-to-fovea distance (FD), and the length of temporal retinal vascularization (LTRV) distance were measured by evaluating pre-treatment and FA images. Results The mean ages at the time of treatment and FA were 40.38  ±  3.35 and 68.72  ±  10.52 weeks postmenstrual age, respectively. The pre-treatment LTRV/FD ratio was 3.11  ±  0.41 in the treated eyes and 3.26  ±  0.43 in the non-treated eyes (p  =  0.053). The final LTRV/FD ratio was 4.23  ±  0.38 in the treated group and 4.33  ±  0.37 in the non-treated group (p  =  0.286). Staining of the vessels, hyperfluorescent focus, and irregular branching of the vessels were similar between the groups, respectively (p  =  1.000; p  =  0.250; p  =  0.625). Conclusion The progression rate of retinal vascularization and angiographic findings were similar between the treated eyes and the non-treated eyes. Our study suggests that incomplete retinal vascularization in eyes treated with anti-vascular endothelial growth factor (VEGF) is due to the nature of the disease, and anti-VEGF treatment was not to cause cessation in vascular progression.

Analysis of intravitreal bevacizumab treatment for macular oedema due to retinal vein occlusion

2020 ◽  
pp. 112067212096205
Author(s):  
Szabolcs Balla ◽  
Eszter Zold ◽  
Laszlo Potor ◽  
Balazs Lukucz ◽  
Attila Vajas ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Retinal Vein Occlusion ◽  
Macular Oedema ◽  
Intravitreal Bevacizumab ◽  
Treated Group ◽  
T Test ◽  
Control Group ◽  
Vein Occlusion ◽  
Bevacizumab Treatment ◽  
The Difference

Purpose: Our aim was to analyse the clinical effect of intravitreal bevacizumab treatment for macular oedema due to central/branch retinal vein occlusion (CRVO/BRVO). The end points were final best-corrected visual acuity (BCVA), BCVA improvement, final central 1-mm macular subfield thickness (CST) and change in CST. Methods: Our study included 34 CRVO and 25 BRVO patients. Patients received intravitreal bevacizumab (IVB) treatment at our department. Our control group consisted of 50 CRVO and 30 BRVO patients, who had not received this treatment because their disease developed before the anti-VEGF treatment became available. For statistical analysis, two-sample t-test, Pearson’s correlation, and ANOVA were used. The level of significance was defined at p < 0.05. Results: With the two-sample t-test we found significant improvement of BCVA in the IVB-treated group (CRVO: 0.171 ± 0.270, p1 = 3.25×10-4; BRVO: 0.215 ± 0.282, p2 = 5.52×10-4). The difference in BCVA improvement was also significant compared to the control group (CRVO: p1 = 3.46×10-4; BRVO: p2 = 0.003). Significant decrease was observed in the CST in the treated group (CRVO: -345.114 ± 280.577, p1 = 6.94×10-9; BRVO: –151.875 ± 174.341, p2 = 1.67×10-4). In case of BRVO patients the final BCVA was significantly better in the treated group (0.617 ± 0.334) compared to the control group (0.406 ± 0.357), p = 0.016. Conclusion: IVB treatment results in significantly better final visual acuity and leads to significantly increased BCVA improvement compared to patients with RVO-induced macular oedema receiving no treatment.

INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION

Retina ◽  
2006 ◽  
Vol 26 (4) ◽  
pp. 383-390 ◽  
Author(s):  
RICHARD F. SPAIDE ◽  
KETAN LAUD ◽  
HOWARD F. FINE ◽  
JAMES M. KLANCNIK ◽  
CATHERINE B. MEYERLE ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Choroidal Neovascularization ◽  
Intravitreal Bevacizumab ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Bevacizumab Treatment

Correlation of response to intravitreal bevacizumab treatment between the first and second treated eyes in diabetic macular edema

2021 ◽  
pp. 112067212110596
Author(s):  
Nadav Levinger ◽  
Liran Tiosano ◽  
Elishai Assayag ◽  
Rivkah Lender ◽  
Tomer Batash ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Intravitreal Bevacizumab ◽  
Thickness Reduction ◽  
Bevacizumab Treatment ◽  
Central Subfield Thickness ◽  
Bilateral Diabetic Macular Edema ◽  
The Mean ◽  
Selection Of

Purpose To evaluate whether outcome of bevacizumab treatment in the first treated eye can guide the selection of compound for the second treated eye in patients with bilateral diabetic macular edema. Methods Demographic, clinical, and optical coherence tomography data were retrospectively collected from consecutive patients who underwent bevacizumab therapy for bilateral diabetic macular edema. Change in central subfield thickness and visual acuity were evaluated and compared between the first treated eye and second treated eye. Results A total of 66 eyes of 33 patients were included in the study. The mean ± SD follow-up time was 13 ± 5 months. The mean ± SD central subfield thickness at baseline was 464 ± 30 μm in the first treated eye and 461 ± 29 μm in the second treated eye ( p = 0.91). Final central subfield thickness was reduced to 392 ± 27 μm in the first treated eye ( p = 0.01 compared with baseline) and 416 ± 25 μm in the second treated eye ( p = 0.03 compared with baseline). Using ≥5% or ≥10% reduction of central subfield thickness as diagnostic criteria to predict similar magnitude of thickness reduction in the first treated eye yielded a positive and negative predictive value ranging from 46% to 81%, and sensitivity and specificity ranging from 54% to 84%. Regression models did not show correlation between central subfield thickness reduction in first treated eye and the second treated eye at the end of follow-up. Conclusions Bevacizumab therapy reduced macular thickness in both eyes in bilateral diabetic macular edema. Treatment outcome of the first treated eye could not predict the outcome of the second treated eye. Particularly, failure to reduce central subfield thickness in the first treated eye does not preclude a favorable response to bevacizumab therapy in the second eye.

Retinal Manifestations of Incontinentia Pigmenti: A Case Series of 14 Patients Highlighting the Importance of Intravenous Fluorescein Angiography and the Benefits of Early Laser Photocoagulation

2020 ◽  
pp. 247412642096264
Author(s):  
Jaimie Bryan ◽  
Reda Issa ◽  
Benjamin Bakall ◽  
Matthew Welch ◽  
J. Shepard Bryan
Keyword(s):  
Fluorescein Angiography ◽  
Laser Photocoagulation ◽  
Vision Loss ◽  
Case Series ◽  
Vitreoretinal Surgery ◽  
Vitreous Hemorrhage ◽  
Fundus Photography ◽  
Incontinentia Pigmenti ◽  
Peripheral Ischemia ◽  
Fundus Photographs

Purpose: This case series describes the nature and frequency of retinal manifestations in patients with incontinentia pigmenti (IP). Methods: This is a retrospective single-center case series of all known patients with IP who presented to Associated Retina Consultants (Phoenix, AZ) between May 2016 and April 2019. Twenty-eight eyes of 14 patients with a dermatologic diagnosis of IP were included (n = 28). Most patients underwent examination under anesthesia with fundus photographs and intravenous fluorescein angiography (IVFA). Results: Of the 28 eyes, 8 (28.6%) had abnormal retinal findings on fundus examination. Of the 26 eyes that had IVFA, 10 (38.5%) had abnormal findings: Seven eyes (26.9%) had peripheral ischemia, 2 (7.7%) had previous peripheral laser scarring, and 2 (7.7%) had active peripheral neovascularization. Three eyes with normal examination results were found to have mild ischemia by IVFA. Patients with ischemia confirmed by IVFA were treated with laser photocoagulation. During follow-up, 4 previously treated eyes received additional laser photocoagulation. No patients showed vision loss, vitreous hemorrhage, retinal detachment, or adverse effects of treatment. No patients required vitreoretinal surgery. Conclusions: IP is a potentially blinding disease. Our case series demonstrates the efficacy of early treatment and the importance of ancillary testing with IVFA and fundus photography.

scholarly journals HEPATOPROTECTIVE ACTIVITY OF AQUEOUS EXTRACT OF OXALIS DEBILIS KUNTH AGAINST CCL4 - INDUCED LIVER DAMAGE

2017 ◽  
Vol 10 (9) ◽  
pp. 231
Author(s):  
Rojini Athokpam ◽  
Meenakshi Bawari ◽  
Manabendra Dutta Choudhury
Keyword(s):  
Aqueous Extract ◽  
Liver Damage ◽  
Elevated Serum ◽  
Treated Group ◽  
Hepatoprotective Activity ◽  
Post Treatment ◽  
Histopathological Study ◽  
Phytochemical Analysis ◽  
Ccl4 Intoxication ◽  
Pre Treatment

  Objective: To evaluate the hepatoprotective activity of aqueous extract of Oxalis debilis Kunth in carbon tetrachloride (CCl4)-induced hepatotoxicity in Swiss albino mice.Methods: Hepatotoxicity was induced by CCl4 30% in olive oil (1 ml/kg intraperitoneally). Mice were treated with aqueous extract of O. debilis at doses of 250 and 500 mg/kg body weight orally for 14 days. There were two groups, pre-treatment (once daily for 14 days before CCl4 intoxication) and post-treatment (2, 6, 24, and 48 hrs after CCl4 intoxication). The observed effects were compared with a known hepatoprotective agent, silymarin.Results: Pre-treatment and post-treatment groups of aqueous extract of O. debilis significantly reduced elevated serum levels of serum transaminases, alkaline phosphatase, and bilirubin and increased the level of total protein as compared to CCl4-treated group. The histopathological study also confirms the hepatoprotection. Preliminary qualitative phytochemical analysis of the plant revealed the presence of phenolic compounds, tannins, flavonoids, and saponins.Conclusion: The results of this study suggest that O. debilis can be used as safe, cheap, and alternative preventive and protective drugs against liver injury. The protective effect observed could be attributed to the presence of various phytochemicals which are responsible for the restoration of liver damage.

IB-367 pre-treatment improves the in vivo efficacy of teicoplanin and daptomycin in an animal model of wounds infected with meticillin-resistant Staphylococcus aureus

2013 ◽  
Vol 62 (10) ◽  
pp. 1552-1558 ◽  
Author(s):  
Oscar Cirioni ◽  
Carmela Silvestri ◽  
Elisa Pierpaoli ◽  
Alessandra Barucca ◽  
Wojciech Kamysz ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Nk Cell ◽  
Antimicrobial Effect ◽  
Treated Group ◽  
Cell Number ◽  
Control Groups ◽  
Pre Treatment ◽  
Leukocyte Populations ◽  
Nk Cytotoxicity

Antimicrobial peptides are known as immunomodulators and antibiotic enhancers. We report that administration of an antimicrobial peptide, IB-367, was efficacious in increasing the antimicrobial activity of daptomycin and teicoplanin in a mouse model of wound infection caused by meticillin-resistant Staphylococcus aureus (MRSA). Mice were assigned to seven groups: an IB-367 pre-treated group with no antibiotics given after challenge, two IB-367 pre-treated groups plus daptomycin or teicoplanin given after challenge, two groups treated with daptomycin or teicoplanin only after challenge, and two control groups without infection or that did not receive any treatment. The main outcome measures were quantitative bacterial culture and analysis of natural killer (NK) cytotoxicity and leukocyte phenotype. The wound, established through the panniculus carnosus muscle of mice, was infected by MRSA. Bacterial cultures of mice receiving antibiotics alone showed a −2 log decrease, whilst those for IB-367 plus daptomycin or teicoplanin showed a −4 log decrease. IB-367 plus daptomycin showed the highest efficacy. The higher antimicrobial effect exerted by IB-367 was associated with increased levels of NK cytotoxicity but not of NK cell number. IB-367 increased the number of both CD11b and Gr-1 cells 3 days after MRSA challenge, whereas both of these leukocyte populations were reduced at 10 days after challenge. Our data suggest that a combination of IB-367 with antibiotic exerts a therapeutic effect and may be useful for the management of staphylococcal wounds.

Sign in / Sign up

Export Citation Format

Share Document